Progress for carbon dioxide geological storage in West Macedonia: A field and laboratory-based survey.

Background: It is widely acknowledged that carbon dioxide (CO 2), a greenhouse gas, is largely responsible for climatic changes that can lead to warming or cooling in various places. This disturbs natural processes, creating instability and fragility of natural and social ecosystems. To combat climate change, without compromising technology advancements and maintaining production costs at acceptable levels, carbon capture and storage (CCS) technologies can be deployed to advance a non-disruptive energy transition. Capturing CO 2 from industrial processes such as thermoelectric power stations, refineries, and cement factories and storing it in geological mediums is becoming a mature technology. Part of the Mesohellenic Basin, situated in Greek territory, is proposed as a potential area for CO 2 storage in saline aquifers. This follows work previously done in the StrategyCCUS project, funded by the EU. The work is progressing under the Pilot Strategy, funded by the EU. Methods: The current investigation includes geomechanical and petrophysical methods to characterise sedimentary formations for their potential to hold CO 2 underground. Results: Samples were found to have both low porosity and permeability while the corresponding uniaxial strength for the Tsotyli formation was 22 MPa, for Eptechori 35 MPa and Pentalofo 74 MPa. Conclusions: The samples investigated indicate the potential to act as cap-rocks due to low porosity and permeability, but fluid pressure within the rock should remain within specified limits; otherwise, the rock may easily fracture and result in CO 2 leakage or/and deform to allow the flow of CO 2. Further investigation is needed to identify reservoir rocks as well more sampling to allow for statistically significant results.

Emphysematous gastritis / Gastritis enfisematosa

No disponible

Multiple myeloma in elderly patients-a Portuguese multicentric real-life study.

Patients older than 75 years old with multiple myeloma (MM) have shorter survival and are usually treated differently from what features in clinical trials. In this study, the authors characterized the Portuguese population of MM patients above 75 years old, treated between 2009 and 2016. We compared the outcomes obtained with bortezomib-based protocols (BBP), thalidomide-based protocols (TBP), and chemotherapy (CT) using univariate and multivariate controlling for age, performance status, International Staging System score, renal impairment, and number of comorbidities. We retrieved data from 386 patients, treated in 12 hospitals. Three hundred thirty-one cases were analyzed: 119 patients treated with BBP, 65 with TBP, 147 with CT. Median age was 79 years; CT-treated patients were older, had a worse performance status, and have more comorbidities. The median follow-up was 25 months. The 2-year OS was 58% and the median OS was 29.5 months. Patients treated with BBP had more frequently very good partial response (VGPR) or better response, and the subgroup of more fit patients had a significantly longer progression-free survival (PFS) and OS. The most frequently grade 3-4 toxicities were hematologic, infectious, and neurologic and were significantly lower in TBP and CT groups vs BBP. The most common second line was CT, followed by lenalidomide. Patients treated with lenalidomide had a higher probability of VGPR or better and a superior 1-year PFS. Despite the limitations of a retrospective study, our cohort represents the reality of older patients with MM in a western country. The hazard of death or progression was higher for old, fit patients treated, in first line, with CT and with TBP compared with that of BBP.

Congenital erythrocytosis - discover of a new mutation in the EGLN1 gene.

Congenital erythrocytosis is a hereditary disorder due to an increase in red cell mass that can be caused by mutations in proteins involved in HIF-α pathway, as PHD2. Hereby, we describe a new familial mutation in PHD2 gene. Considering an increased thrombotic potential, patients began antiplatelet aggregation therapy and phlebotomies.